Removal of generic drugs from WHO list a wake-up call
Sunday 22 August 2004
Home About PlusNews Country Profiles News Briefs Special Reports Subscribe Archive IRINnews

Regions

Africa
East Africa
Great Lakes
Horn of Africa
Southern Africa
Angola
Botswana
Comoros
Lesotho
Madagascar
Malawi
Mauritus
Mozambique
Namibia
South Africa
Swaziland
Zambia
Zimbabwe
West Africa
RSSyndication

Features

PlusNews E-mail Subscription

AFRICA: Removal of generic drugs from WHO list a wake-up call


[This report does not necessarily reflect the views of the United Nations]


JOHANNESBURG, 6 August (PLUSNEWS) - The removal of Indian-manufactured generic antiretroviral (ARV) drugs from the World Health Organisation's (WHO) list of approved HIV medicine this week should be a wake-up call for developing countries with slack regulatory authorities, experts warned.

The three drugs, made by India's Ranbaxy Laboratories, were removed following concerns raised over their biological equivalence to the patented versions.

According to WHO project manager Andre van Zyl, laboratories which had done bioequivalence studies for the approved drugs on the list were inspected "as part of WHO's ongoing monitoring process". Recent inspections revealed that a laboratory contracted by Ranbaxy did not comply with international standards.

This meant that "the medicines may or may not offer the same therapeutic benefits as the originals on which they are based," a WHO press release noted.

The non-compliant ARVs are the triple fixed-dose combination pill containing Lamivudine, Stavudine and Nevirapine in two different strengths, and a Lamivudine plus Zidovudine tablet.

Although the Ranbaxy triple combination pill was one of the recommended standard treatments for HIV-positive people, "there are similar products from different manufacturers which can be used as an alternative," van Zyl told PlusNews.

Earlier this year WHO removed two generic drugs made by Cipla, another Indian pharmaceutical company, from its approved list after an evaluation revealed similar non-compliance by a subcontracted laboratory.

Van Zyl urged developing countries with inadequate drug assessment procedures to be more cautious. "This shows that one has to be more rigorous and verify that what has been submitted by the manufacturer is what it purports to be. This is especially so when the products have a critical therapeutic outcome," he said.

While the WHO announcement was "certainly a cause for concern", the direct impact of this decision would vary from country to country, Andy Gray, senior pharmacology lecturer at the University of KwaZulu-Natal in South Africa, told PlusNews.

"If a country has its own stringent regulatory procedures, the WHO prequalification will not have a direct impact, as the data submitted to the country will be from a different source. The bioequivalence tests might have been done at a different site [from the one WHO inspected]" he added.

A bigger question was whether people currently on the Ranbaxy treatment would be allowed to continue using the drugs, Gray pointed out. Countries relying on Global AIDS Fund resources for their treatment programmes, for example, would not be able to continue using the drugs, as the Fund stipulated that only WHO-approved ARVs could be used.

Gray also questioned whether there was "truly a problem" with the drugs, or whether the removal had been "simply about paperwork".

Nevertheless, he noted, regulatory authorities in each country would have to play a greater role.

[ENDS]


Recent AFRICA Reports
IRIN PlusNews Weekly Issue 195, 20 August 2004, 20/Aug/04
HIV-positive women speak out, 17/Aug/04
Sexual Offences bill raises many concerns, 13/Aug/04
IRIN PlusNews Weekly Issue 194, 13 August 2004, 13/Aug/04
Campaign to create awareness on sexual offences law, 6/Aug/04
Links
The Global Fund to fight AIDS, Tuberculosis & Malaria
AEGIS
The Global Fund to fight AIDS, Tuberculosis & Malaria
Mothers and HIV/AIDS

PlusNews does not take responsibility for info in links supplied.

PARTNERS

PlusNews is produced under the banner of RHAIN, the Southern African Regional HIV/AIDS Information Network. RHAIN's members currently include:

  • UNAIDS
  • IRIN
  • Inter Press Service (IPS)
  • SAfAIDS
  • PANOS
  • Health Systems Trust
  • Health & Development Networks
  • GTZ/Afronets

[Back] [Home Page]

Click to send any feedback, comments or questions you have about IRIN's Website or if you prefer you can send an Email to

The material contained on this Web site comes to you via IRIN, a UN humanitarian information unit, but may not necessarily reflect the views of the United Nations or its agencies. If you re-print, copy, archive or re-post any item on this site, please retain this credit and disclaimer. Quotations or extracts should include attribution to the original sources. All graphics and Images on this site may not be re-produced without the express permission of the original owner. All materials copyright UN Office for the Coordination of Humanitarian Affairs 2004